118 related articles for article (PubMed ID: 26349961)
1. Homology modeling, binding site identification and docking study of human angiotensin II type I (Ang II-AT1) receptor.
Vyas VK; Ghate M; Patel K; Qureshi G; Shah S
Biomed Pharmacother; 2015 Aug; 74():42-8. PubMed ID: 26349961
[TBL] [Abstract][Full Text] [Related]
2. Chronic production of angiotensin IV in the brain leads to hypertension that is reversible with an angiotensin II AT1 receptor antagonist.
Lochard N; Thibault G; Silversides DW; Touyz RM; Reudelhuber TL
Circ Res; 2004 Jun; 94(11):1451-7. PubMed ID: 15117826
[TBL] [Abstract][Full Text] [Related]
3. Multiple templates-based homology modeling enhances structure quality of AT1 receptor: validation by molecular dynamics and antagonist docking.
Sokkar P; Mohandass S; Ramachandran M
J Mol Model; 2011 Jul; 17(7):1565-77. PubMed ID: 20924625
[TBL] [Abstract][Full Text] [Related]
4. Unique "delta lock" structure of telmisartan is involved in its strongest binding affinity to angiotensin II type 1 receptor.
Ohno K; Amano Y; Kakuta H; Niimi T; Takakura S; Orita M; Miyata K; Sakashita H; Takeuchi M; Komuro I; Higaki J; Horiuchi M; Kim-Mitsuyama S; Mori Y; Morishita R; Yamagishi S
Biochem Biophys Res Commun; 2011 Jan; 404(1):434-7. PubMed ID: 21130741
[TBL] [Abstract][Full Text] [Related]
5. Angiotensin receptor blocker selectivity at the AT1- and AT2-receptors: conceptual and clinical effects.
Unger T; Sandmann S
J Renin Angiotensin Aldosterone Syst; 2000 Jun; 1(2 Suppl):S6-9. PubMed ID: 17199211
[TBL] [Abstract][Full Text] [Related]
6. Understanding electrostatic and steric requirements related to hypertensive action of AT(1) antagonists using molecular modeling techniques.
da C Silva D; Maltarollo VG; de Lima EF; Weber KC; Honorio KM
J Mol Model; 2014 Jul; 20(7):2231. PubMed ID: 24935104
[TBL] [Abstract][Full Text] [Related]
7. Structural determinants for binding, activation, and functional selectivity of the angiotensin AT1 receptor.
Balakumar P; Jagadeesh G
J Mol Endocrinol; 2014 Oct; 53(2):R71-92. PubMed ID: 25013233
[TBL] [Abstract][Full Text] [Related]
8. Design and synthesis of new tetrazolyl- and carboxy-biphenylylmethyl-quinazolin-4-one derivatives as angiotensin II AT1 receptor antagonists.
Ismail MA; Barker S; Abou el-Ella DA; Abouzid KA; Toubar RA; Todd MH
J Med Chem; 2006 Mar; 49(5):1526-35. PubMed ID: 16509571
[TBL] [Abstract][Full Text] [Related]
9. Systematic characterization of AT1 receptor antagonists with label-free dynamic mass redistribution assays.
Qu L; Wang J; Hou T; Zhou H; Wang Z; Zhang X; Liang X
J Pharmacol Toxicol Methods; 2020; 102():106682. PubMed ID: 32087363
[TBL] [Abstract][Full Text] [Related]
10. Sympatho-inhibitory properties of various AT1 receptor antagonists.
Balt JC; Mathy MJ; Pfaffendorf M; van Zwieten PA
J Hypertens Suppl; 2002 Jun; 20(5):S3-11. PubMed ID: 12184061
[TBL] [Abstract][Full Text] [Related]
11. The discovery of new potent non-peptide Angiotensin II AT1 receptor blockers: a concise synthesis, molecular docking studies and biological evaluation of N-substituted 5-butylimidazole derivatives.
Agelis G; Resvani A; Durdagi S; Spyridaki K; Tůmová T; Slaninová J; Giannopoulos P; Vlahakos D; Liapakis G; Mavromoustakos T; Matsoukas J
Eur J Med Chem; 2012 Sep; 55():358-74. PubMed ID: 22889560
[TBL] [Abstract][Full Text] [Related]
12. Ligand-supported homology modeling of the human angiotensin II type 1 (AT(1)) receptor: insights into the molecular determinants of telmisartan binding.
Patny A; Desai PV; Avery MA
Proteins; 2006 Dec; 65(4):824-42. PubMed ID: 17034041
[TBL] [Abstract][Full Text] [Related]
13. Model of the whole rat AT1 receptor and the ligand-binding site.
Baleanu-Gogonea C; Karnik S
J Mol Model; 2006 Feb; 12(3):325-37. PubMed ID: 16404618
[TBL] [Abstract][Full Text] [Related]
14. Pharmacophore, drug metabolism, and pharmacokinetics models on non-peptide AT1, AT2, and AT1/AT2 angiotensin II receptor antagonists.
Berellini G; Cruciani G; Mannhold R
J Med Chem; 2005 Jun; 48(13):4389-99. PubMed ID: 15974591
[TBL] [Abstract][Full Text] [Related]
15. Design and synthesis of novel antihypertensive drugs.
Moutevelis-Minakakis P; Gianni M; Stougiannou H; Zoumpoulakis P; Zoga A; Vlahakos AD; Iliodromitis E; Mavromoustakos T
Bioorg Med Chem Lett; 2003 May; 13(10):1737-40. PubMed ID: 12729654
[TBL] [Abstract][Full Text] [Related]
16. Emerging concepts of regulation of angiotensin II receptors: new players and targets for traditional receptors.
Mogi M; Iwai M; Horiuchi M
Arterioscler Thromb Vasc Biol; 2007 Dec; 27(12):2532-9. PubMed ID: 17717300
[TBL] [Abstract][Full Text] [Related]
17. Conformation and bioactivity. Design and discovery of novel antihypertensive drugs.
Mavromoustakos T; Zervou M; Zoumpoulakis P; Kyrikou I; Benetis NP; Polevaya L; Roumelioti P; Giatas N; Zoga A; Minakakis PM; Kolocouris A; Vlahakos D; Grdadolnik SG; Matsoukas J
Curr Top Med Chem; 2004; 4(4):385-401. PubMed ID: 14965308
[TBL] [Abstract][Full Text] [Related]
18. [Mechanisms underlying angiotensin II-independent activation of angiotensin II type 1 receptor].
Akazawa H; Komuro I
Nihon Rinsho; 2012 Sep; 70(9):1492-8. PubMed ID: 23012793
[TBL] [Abstract][Full Text] [Related]
19. Oral administration of an AT1 receptor antagonist prevents the central effects of angiotensin II in spontaneously hypertensive rats.
Seltzer A; Bregonzio C; Armando I; Baiardi G; Saavedra JM
Brain Res; 2004 Nov; 1028(1):9-18. PubMed ID: 15518636
[TBL] [Abstract][Full Text] [Related]
20. Research Progress in Pharmacological Mechanisms, Structure-Activity Relationship and Synthesis of Sartans.
Wang YF; Ren XY; Zhang W; Rao GW
Curr Med Chem; 2023; 30(20):2247-2266. PubMed ID: 36043743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
